Original Research Article
May 18, 2022
Online Learning and Quality of Higher Education: A Comparative Analysis from Chhattisgarh
Dr. Susobhan Maiti, Avichal Sharma, Pallavi Pandey
None | 184-189
DOI : 10.36347/sjahss.2022.v10i05.004
This study has revealed a growing gap between level of higher education in public and private universities due to introduction of technological means as essential teaching aids. In India, the most serious issue is money of the necessary devices. Cellular data is not available even if gadgets are available. The biggest sticking point for government universities is enticing users to study online classes. For most students, online education has been a hardship due to a complete lack of a smart phone or internet access. Putting the state of Chhattisgarh under scanner, it has been observed that the quality of education in higher educational institutes varies markedly amongst government and private universities. This study analyses the issues and concerns that exacerbate the disparity between private and public institutions and measured quality of higher education. Striking distinguishing features such as classroom infrastructure, teacher quality, extra-curricular programs, and more may be visibly detected. While technology can be advantageous, it can sometimes be constraining, particularly in tribal states like Chhattisgarh, where basic access is limited. Not every student has access to a computer at home or to high-speed internet. Most students are apprehensive about their future as they failed to properly attend even a single online lecture because their parents could not afford the expense, plus streaming technologies appeared to be a significant financial strain. Other challenges beset both students and faculty in this mode of education. On the one extreme, private institution have seamlessly sustained online classes, whilst government universities have gone off the rails.
A Comprehensive Review of the Analytical Development and Validation of Alprazolam in Bulk and Pharmaceutical Dosage Form
Gaurav M. Prajapati, Devang R. Ghuge
None | 88-93
DOI : 10.36347/sajp.2022.v11i05.004
Alprazolam is approved in 2003 by US FDA. Alprazolam is available as an extended-release tablet, a mouth dissolving tablet (a tablet that dissolves rapidly in the mouth), as well as a concentrated solution (liquid). For the treatment of severe anxiety and panic disorder, alprazolam is one of the most commonly prescribed benzodiazepines. IPUAC name of Alprazolam is 8-Chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a] [1, 4] benzodiazepine. The molecular formula and molecular Weight is C17H12ClFN4 and 326.75 g/mol. These articles may serve as an overview of Alprazolam with their drug profile, pharmacology, pharmacokinetics, and analytical HPLC procedures that are commonly employed in determining common provision issues. These reviews cover topics such as mobile phase, mobile phase ratio, column, retention time, flow rate, UV detector wavelength, run time, and more. Linearity, percent recovery, detection limit, and quantification limit are all validating parameters. The pharmaceutical analysis serves as an internal control for pure and pharmaceutical dosage forms, which is critical for quality assurance. The development of analytical methods has emerged as a crucial study activity.
Original Research Article
May 12, 2022
Response of Thalidomide in Hemoglobin Increment of Transfusion Dependent Thalassemia
Dr. Md. Ashikuzzaman
None | 685-690
DOI : 10.36347/sjams.2022.v10i05.003
Background: Thalassemia is the most common single gene hereditary disease worldwide. Hb E-β Thalassemia is the commonest severe form of thalassemia in south-east Asia including Bangladesh. The clinical benefit of increased Hb-F in thalassemia treatment is well established which act by decreasing the imbalance between α & non α chains and the consequent reduction of haemolysis. Recent study showed outstanding results on haemoglobin level and transfusion requirement in thalassemia patients treated with thalidomide. Objective: Aims of our study is evaluate the response of thalidomide in hemoglobin increment of transfusion dependent thalassemia. Method: In this quasi-experimental study 50 patients >12 years old attended in Thalassemia clinic, Department of Haematology, Dhaka Medical College & Hospital, Dhaka were recorded as study cases. All relevant collected prospectively from patients and recorded in prescribed form (Data collection sheet). After full explanation, informed written consent was taken from the selected patients informing the details of the purpose of the study. Data processed and analyzed with the help of computer programme SPSS (Statistical package for social sciences) win version 25 & presented in the form of tables, graphs & chart. Result: In study cases it was found that there was significant increment of Hb, Hematocrit, HbF% and improvement of performance status 6months after thalidomide therapy (mean 6.36 ±0.78 vs 7.49±0.59, 19.89±2.57 vs 25.88±2.47, 23.03±14.61% vs 39.42±13.31% and 2.24±0.43 vs 1.50±0.54; respectively; all p <0.001). It also reveled that after 6 months of thalidomide therapy there were significant reduction of transfusion requirement, spleen size, nRBC count, Serum LDH, Serum Bilirubin (total) and Serum ferritin (100.06±27.2 vs 54.48±18.34 ml/kg/year, 12.3±6.73 vs 9.28±5.26 cm, 42.28±61.02 vs 16.96±30.14 nRBC/100 WBC, 502.60±124.54 vs 413.28±152.43 U/L, 3.00±1.36 vs 2.12±0.78 mg/dl, 2235.3±2225.6 vs 1574.9±1540.7; ........